Interestingly, the “sandwich strategy” based on afatinib exhibited significant activity, with an ORR of 29% and a median PFS of 4.7 months in advanced EGFR-mutant NSCLC and acquired resistance to erlotinib/gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.